Postpartum Low-Dose Aspirin and Preeclampsia

Description

The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.

Conditions

Preeclampsia Postpartum

Study Overview

Study Details

Study overview

The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.

Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients With Preeclampsia

Postpartum Low-Dose Aspirin and Preeclampsia

Condition
Preeclampsia Postpartum
Intervention / Treatment

-

Contacts and Locations

New York

Columbia University Irving Medical Center, New York, New York, United States, 10032

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Singleton or Multiple gestation
  • * Maternal age \>= 18 years
  • * 20 0/7 weeks gestation or greater
  • * Severe Preeclampsia diagnosed prior to delivery
  • * Aspirin use postpartum for other medical indication
  • * Lovenox, unfractionated heparin, or other anticoagulant use postpartum for an indication other than postoperative (in-house)
  • * Aspirin use within 7 days of planned initial FMD testing postpartum
  • * Hypersensitivity or allergy to Aspirin or other salicylates
  • * Hypersensitivity or allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) - exception if taking LDA in pregnancy
  • * Nasal polyps
  • * Gastric or Duodenal ulcers, history of GI bleeding
  • * Severe hepatic dysfunction
  • * Bleeding disorders and diathesis
  • * Breastfeeding a newborn with low platelets (NAIT)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Columbia University,

Aleha Aziz, MD, MPH, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

2025-12